Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genscript Biotech ( (HK:1548) ) has provided an announcement.
Genscript Biotech Corporation announced the grant of 624,540 Restricted Shares to its rotating chief executive officer and a director under the 2019 RSA Scheme. This move is part of the company’s strategy to align the interests of its executives with corporate performance, with vesting periods extending up to five years and performance targets in place. The inclusion of a clawback mechanism ensures that the company can reclaim equity incentives under certain conditions, such as misconduct or financial misstatements.
More about Genscript Biotech
Genscript Biotech Corporation is a company incorporated in the Cayman Islands, operating in the biotechnology industry. The company, along with its subsidiaries, focuses on providing innovative biotechnology products and services.
Average Trading Volume: 22,411,448
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.41B
For a thorough assessment of 1548 stock, go to TipRanks’ Stock Analysis page.